BridgeBio Pharma’s Canavan Disease Treatment BBP-812 Granted FDA Regenerative Medicine Advanced Therapy Designation
In a breakthrough for genetic diseases treatment, BridgeBio Pharma's Canavan disease therapy BBP-812 has received Regenerative Medicine Advanced Therapy...